Mixed effects model results for primary outcomes, repeated visits
| Outcome . | Difference in therapy group (HU vs no therapy) estimate (95% CI) . | P value . |
|---|---|---|
| Total sleep time | 5.52 (−15.72 to 26.76) | .60 |
| Sleep efficiency | −0.06 (−4.47 to 4.34) | .98 |
| Arousals | 1.83 (−0.58 to 4.25) | .14 |
| Baseline SpO2 at PSG start, % | −0.93 (−1.75 to −0.11) | .027∗ |
| NREM sleep SpO2 nadir, % | 0.52 (−1.01 to 2.06) | .49 |
| REM sleep SpO2 nadir, % | 1.13 (−0.82 to 3.07) | .25 |
| Percentage of sleep with SpO2 <90% | 1.79 (−1.68 to 5.26) | .31 |
| AHI | 0.22 (−1.09 to 1.53) | .74 |
| OHI | 0.29 (−0.94 to 1.53) | .64 |
| REM AHI | 1.46 (−3.97 to 6.90) | .60 |
| Outcome . | Difference in therapy group (HU vs no therapy) estimate (95% CI) . | P value . |
|---|---|---|
| Total sleep time | 5.52 (−15.72 to 26.76) | .60 |
| Sleep efficiency | −0.06 (−4.47 to 4.34) | .98 |
| Arousals | 1.83 (−0.58 to 4.25) | .14 |
| Baseline SpO2 at PSG start, % | −0.93 (−1.75 to −0.11) | .027∗ |
| NREM sleep SpO2 nadir, % | 0.52 (−1.01 to 2.06) | .49 |
| REM sleep SpO2 nadir, % | 1.13 (−0.82 to 3.07) | .25 |
| Percentage of sleep with SpO2 <90% | 1.79 (−1.68 to 5.26) | .31 |
| AHI | 0.22 (−1.09 to 1.53) | .74 |
| OHI | 0.29 (−0.94 to 1.53) | .64 |
| REM AHI | 1.46 (−3.97 to 6.90) | .60 |
P < .05.